Repurposing recombinant IL-2 (aldesleukin) for treating human cardiovascular disease is of interest, although currently its licensed indication is limited to metastatic melanoma and metastatic renal cell carcinoma. The gene discussed is IL2; the disease is metastatic melanoma.